S110 preclinical data presented by Dr. Peter Jones, Director of USC's
Norris Cancer Center
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that S110, the Company's decitabine-derived DNA demethylating agent, shows improved pre-clinical activity due to increased drug delivery and stability (Poster 140). Additionally, Dr. Peter A. Jones, Director of USC's Norris Cancer Center, further discussed S110 in the plenary session on cancer epigenetics.
Poster B140 (Abstract No. 1038)
The Decitabine-derived Demethylating Dinucleotide S110 Shows Improved Activity Due to Increased Drug Delivery and Stability
Data presented in this poster explains how SuperGen scientists improved the stability of S110 over decitabine in human plasma. S110 demonstrated similar or improved activity compared to decitabine in re-expression of p15, p16, and MLH1 genes, which are silenced in cancer through methylation. S110 delivers decitabine with improved preclinical pharmacokinetics, and has a similar impact on HbF in non-human primates. The dinucleotide S110 is highly resistant to cytidine deaminase degradation in pre-clinical studies. This can potentially lead to longer half-life, improved bioavailability, and lower the dose requirement in patients, and therefore reduce toxicity.
Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site: http://www.supergen.com
"SuperGen has achieved a leadership position in the development of epigenetic therapies with decitabine. S110 represents our continued commitment to this important therapeutic area. We look forward to advancing this compound into the clinic next year," said Dr. James Manuso, SuperGen's President and CEO.
Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.
Timothy L. Enns Mary M. Vegh
SuperGen, Inc. SuperGen, Inc.
SVP, Corporate Communications & Manager, Investor Relations
Business Development Tel: (925) 560-2845
Tel: (925) 560-0100 E-mail: email@example.com
|SOURCE SuperGen Inc.|
Copyright©2007 PR Newswire.
All rights reserved